- Home
- ANL vs SRTS Comparison
ANL vs SRTS Comparison
Compare ANL & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- SRTS
- Stock Information
- Founded
- ANL 2004
- SRTS 2010
- Country
- ANL Cayman Islands
- SRTS United States
- Employees
- ANL N/A
- SRTS N/A
- Industry
- ANL
- SRTS Medical/Dental Instruments
- Sector
- ANL
- SRTS Health Care
- Exchange
- ANL Nasdaq
- SRTS Nasdaq
- Market Cap
- ANL 73.8M
- SRTS 83.9M
- IPO Year
- ANL 2023
- SRTS 2016
- Fundamental
- Price
- ANL $1.47
- SRTS $4.71
- Analyst Decision
- ANL Buy
- SRTS Strong Buy
- Analyst Count
- ANL 2
- SRTS 3
- Target Price
- ANL N/A
- SRTS $11.67
- AVG Volume (30 Days)
- ANL 14.8K
- SRTS 57.4K
- Earning Date
- ANL 08-08-2025
- SRTS 08-07-2025
- Dividend Yield
- ANL N/A
- SRTS N/A
- EPS Growth
- ANL N/A
- SRTS N/A
- EPS
- ANL N/A
- SRTS 0.11
- Revenue
- ANL N/A
- SRTS $39,488,000.00
- Revenue This Year
- ANL N/A
- SRTS $4.33
- Revenue Next Year
- ANL N/A
- SRTS $31.55
- P/E Ratio
- ANL N/A
- SRTS $42.87
- Revenue Growth
- ANL N/A
- SRTS 24.75
- 52 Week Low
- ANL $1.10
- SRTS $4.01
- 52 Week High
- ANL $4.10
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- ANL 37.32
- SRTS 50.14
- Support Level
- ANL $1.56
- SRTS $4.72
- Resistance Level
- ANL $1.74
- SRTS $5.02
- Average True Range (ATR)
- ANL 0.15
- SRTS 0.21
- MACD
- ANL -0.01
- SRTS -0.03
- Stochastic Oscillator
- ANL 12.50
- SRTS 27.12
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.